Leerink Partnrs Issues Positive Outlook for Pfizer Earnings

Pfizer Inc. (NYSE:PFE) – Investment analysts at Leerink Partnrs lifted their FY2025 earnings estimates for Pfizer in a report issued on Wednesday, December 18th. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $2.90 per share for the year, up from their previous estimate of $2.82. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.17) earnings per share.

Other equities analysts also recently issued reports about the stock. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Truist Financial reduced their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Sanford C. Bernstein started coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.14.

Pfizer Stock Performance

NYSE:PFE opened at $26.71 on Monday. The firm has a market capitalization of $151.37 billion, a PE ratio of 36.10, a PEG ratio of 0.63 and a beta of 0.65. The stock’s fifty day moving average is $26.82 and its 200 day moving average is $28.16. Pfizer has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Institutional Trading of Pfizer

Several large investors have recently made changes to their positions in the business. Gladius Capital Management LP raised its stake in shares of Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the last quarter. Quarry LP acquired a new position in Pfizer in the second quarter valued at approximately $31,000. Financial Connections Group Inc. purchased a new position in shares of Pfizer during the 2nd quarter valued at approximately $34,000. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer during the third quarter valued at $35,000. Finally, Joseph Group Capital Management increased its holdings in Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 771 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a yield of 6.44%. Pfizer’s dividend payout ratio (DPR) is 232.43%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.